Posted by Sherry C. on Monday, December 2nd, 2013
There are some very exciting new clinical trials that have shown a new medical food therapy (available now in the US) may help some patients with Alzheimer’s disease (AD).
A recent study of the effectiveness of caprylic triglyceride (CT) – the active ingredient in a non-drug prescription called Axona, was conducted by Dr. Steven Douglas Maynard and Dr. Jeff Gelblum at Indiana University/Mount Sinai Medical Center. The research article was published in the Neuropsychiatric Disease and Treatment Journal in October 2013.
The primary reason for the study was to evaluate the effects of CT in those with mild to moderate AD in a routine clinical practice setting. The effect of CT was evaluated in the study by medical records reviews by the physicians, as well as reports from caregivers who were asked to answer questionnaires at specific intervals during the study period.
The study included male and female participants age 50 and over, diagnosed with probable mild to moderate AD who had received this new prescription-only medical food for over 6 months.
The results of the study were encouraging. Of a total of 55 participants who took Axona in addition to medications for AD, 80 percent were stable or had improvement in cognition. This was after an average of over 18 months of taking Axona, where 36.9% of the participants in the study improved (and 80% of patients improved or remained stable).